Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Annals of Oncology

• Publication date

  2017-06-01

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1093/annonc/mdx108PMID 28368458
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bacteroides fragilis Lipopolysaccharide and Inflammatory Signaling in Alzheimer’s Disease

  2016cited by this paper
• Gut microbiome derived metabolites modulate intestinal epithelial cell damage and mitigate Graft-versus-Host Disease

  2016cited by this paper
• Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

  2016influential reference
• Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

  2016cited by this paper
• Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.

  2016influential reference
• Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes

  2015influential reference
• Immune Checkpoint Blockade in Cancer Therapy.

  2015cited by this paper
• Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

  2015influential reference
• Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015influential reference
• Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

  2015cited by this paper
• The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases

  2015cited by this paper
• Systematic review: colitis associated with anti‐CTLA‐4 therapy

  2015cited by this paper
• IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients.

  2014cited by this paper
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014cited by this paper
• Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings

  2014cited by this paper
• The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic Treg Cell Homeostasis

  2013cited by this paper
• Faculty Opinions recommendation of Thymus-derived regulatory T cells contribute to tolerance to commensal microbiota.

  2013cited by this paper
• Richness of human gut microbiome correlates with metabolic markers

  2013cited by this paper
• Thymus-derived regulatory T cells control tolerance to commensal microbiota

  2013cited by this paper
• Phase I clinical trial combining imatinib mesylate and IL-2

  2013cited by this paper
• Reciprocal interactions of the intestinal microbiota and immune system

  2012cited by this paper
• Analyzing Survival Data with Competing Risks Using SAS ® Software

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Management of immune-related adverse events and kinetics of response with ipilimumab.

  2012cited by this paper
• Inflammatory bowel disease.

  2011cited by this paper
• Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis.

  2011cited by this paper
• The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases.

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.

  2011cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Mucolytic Bacteria With Increased Prevalence in IBD Mucosa Augment In Vitro Utilization of Mucin by Other Bacteria

  2010cited by this paper
• Inflammatory bowel disease.

  2009cited by this paper
• Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

  2009cited by this paper
• Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues

  2009cited by this paper
• Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients

  2008cited by this paper
• CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

  2008cited by this paper
• Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4

  2008cited by this paper
• The inflammatory status of old age can be nurtured from the intestinal environment

  2008cited by this paper
• Metabolism of Linoleic Acid by Human Gut Bacteria: Different Routes for Biosynthesis of Conjugated Linoleic Acid

  2007cited by this paper
• Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

  2006cited by this paper
• Blockade of CTLA-4 on CD4+CD25+ Regulatory T Cells Abrogates Their Function In Vivo1

  2006cited by this paper
• Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon

  2003cited by this paper
• ICOS Costimulation Requires IL-2 and Can Be Prevented by CTLA-4 Engagement1

  2001cited by this paper
• A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk

  1988cited by this paper
• In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration.

  1987cited by this paper

• Clinical Analysis of Peripheral Blood Indicators for Immune-Related Adverse Events (irAEs) in Patients With Advanced Lung Cancer

  2026cites this paper
• Assessment of Fecal Microbiota in Healthy Dogs and Dogs with Cutaneous Mast Cell Tumors Treated with Electrochemotherapy Combined with Gene Electrotransfer of IL-12

  2026cites this paper
• Gut Microbiome Strategies for Enhancing ICI Delivery Across the BBB in Glioblastoma

  2026cites this paper
• Killing cancer takes guts: lessons learned from the manipulation of gut microbiome and immunotherapy for the future of urothelial carcinoma

  2026cites this paper
• Gut microbiota drives cancer evolution and therapy resistance

  2026cites this paper
• The Role of the Microbiota in Cancer Drug Resistance and Emerging Therapeutic Strategies.

  2026cites this paper
• Cemiplimab in the treatment of cutaneous squamous cell carcinoma.

  2026cites this paper
• Toward Microbiome-Informed Melanoma Care: The Gut Microbiota in Melanoma Evolution, Immunotherapy Response and Immune-Related Toxicity

  2026cites this paper
• When checkpoint inhibitors break barriers: Mechanisms and challenges of irAEs of the skin, gastrointestinal tract, and lung.

  2026cites this paper
• VERU-111 Promotes an Anti-Tumor Response Through Restoration of Gut Microbial Homeostasis and Associated Metabolic Dysregulation

  2026cites this paper
• Osteoporosis and gut microbiota: current understandings

  2026cites this paper
• Sunite sheep tail fat alleviates ulcerative colitis by regulating intestinal flora and metabolites to activate PPAR signaling pathway

  2026cites this paper
• Microbiome modulation of tumorigenesis and immune responses

  2026cites this paper
• Tumor Immunotherapy and Microbiome: From Bench‐to‐Bedside Applications

  2026cites this paper
• GDF15 in the tumor microenvironment: A central mediator of cancer immunometabolism and therapeutic resistance.

  2026cites this paper
• Dynamic circulating biomarkers for predicting adverse events in PRaG therapy: a pooled analysis and model construction from PRaG series clinical trials

  2026cites this paper
• Distinct gut virome profiles are associated with response to anti-PD-1 therapy in non-small cell lung cancer.

  2026cites this paper
• The Gut–Brain–Immune Axis in Glioma: Emerging Mechanisms and Therapeutic Opportunities

  2026cites this paper
• Steroid-sparing strategies for managing immune-related adverse events

  2026cites this paper
• Microbiome-Modulated Immunotherapy in Oncology: Current Applications and Future Prospects.

  2026cites this paper
• The resilient microbiome: how baseline gut microbial composition influences response to cancer treatment.

  2026cites this paper
• Risk factors and clinical course of inflammatory bowel disease in patients receiving cancer therapy.

  2026cites this paper
• Itacitinib in advanced hepatocellular cancer following first line therapy

  2026cites this paper
• Invisible influencers: the tumor microbiome’s impact on immunotherapy in colorectal cancer (CRC)

  2025cites this paper
• Harnessing biomarkers to guide immunotherapy in esophageal cancer: toward precision oncology

  2025cites this paper
• Current status of management of immune-related adverse events and practical needs for oncologist education

  2025cites this paper
• Perspectives on the gut microbiota in patients with non-small cell lung cancer—Two-Sample Mendelian Randomization combined with bibliometric analysis (2001–2023)

  2025cites this paper
• Dermatotoxicity of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Current Advances in Mechanistic Insights and Predictive Biomarker Identification

  2025cites this paper
• Harnessing gut microbiota for colorectal cancer therapy: from clinical insights to therapeutic innovations

  2025cites this paper
• Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions

  2025cites this paper
• Cancer Immunotherapy in Combination with Radiotherapy and/or Chemotherapy: Mechanisms and Clinical Therapy

  2025cites this paper
• The microbiome in cancer

  2025cites this paper
• Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real-world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab

  2025cites this paper
• Global research trends on the relationship between gut microbiota and melanoma from 2014 to 2023: a bibliometric and visualization analysis

  2025cites this paper
• Genetic causality linking skin microbiota to skin cancer: Mendelian randomization study and meta-analysis

  2025cites this paper
• Gut dysbiosis in cancer immunotherapy: microbiota-mediated resistance and emerging treatments

  2025cites this paper
• Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors

  2025cites this paper
• Does a link exist between oral microbiota and oral squamous cell carcinoma? A review of current insights

  2025cites this paper
• Prospect of interdisciplinary research on gut microbiota and colorectal cancer immunotherapy.

  2025cites this paper
• Mitigation strategies for gastrointestinal (GI) immune-related adverse events for patients with solid tumors receiving immunotherapy.

  2025cites this paper
• Nutrition and Diet Patterns as Key Modulators of Metabolic Reprogramming in Melanoma Immunotherapy

  2025cites this paper
• Link between dysbiosis and cancer: Contributing mechanisms and factors.

  2025cites this paper
• The Role of the Gut Microbiome in Non-Hodgkin Lymphoma (NHL): A Focus on Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Cutaneous T-Cell Lymphoma, and NK/T-Cell Lymphoma

  2025cites this paper
• Gut Microbiota Modulation through Akkermansia spp. Supplementation Increases CAR T-cell Potency

  2025cites this paper
• Fecal Microbiota Transplantation for Immune Regulation: Improving Ulcerative Colitis and Enhancing Cancer Immunotherapy.

  2025cites this paper
• Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy.

  2025cites this paper
• Gut microbiota shapes cancer immunotherapy responses

  2025cites this paper
• Gastrointestinal Infection Before Immune Checkpoint Inhibition Hinders Treatment Efficacy and Increases the Risk of Colitis

  2025influential citation
• Microbiome-metabolome generated bile acids gatekeep infliximab efficacy in Crohn's disease by licensing M1 suppression and Treg dominance.

  2025cites this paper
• Characteristics of Intestinal Barrier State and Immunoglobulin-Bound Fraction of Stool Microbiota in Advanced Melanoma Patients Undergoing Anti-PD-1 Therapy

  2025cites this paper
• Recent Abdominal Surgery as a Risk Factor for Unfavorable Immune-Mediated Colitis Outcomes

  2025cites this paper
• Integration of multi-omics approaches in exploring intra-tumoral heterogeneity

  2025cites this paper
• Effect of a Novel Food Rich in Miraculin on the Intestinal Microbiome of Malnourished Patients with Cancer and Dysgeusia

  2025cites this paper
• Insights into the Mechanisms of Immune‐Checkpoint Inhibitors Gained from Spatiotemporal Dynamics of the Tumor Microenvironment

  2025cites this paper
• Microbiome unlocks cancer immunotherapeutic potential: state of the art and future.

  2025cites this paper
• Clinical Evidence for Microbiome-Based Strategies in Cancer Immunotherapy: A State-of-the-Art Review

  2025cites this paper
• Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab – a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial)

  2025cites this paper
• Innate and adaptive immune features associated with immune-related adverse events

  2025cites this paper
• Microbial metabolic pathways guide response to immune checkpoint blockade therapy.

  2025cites this paper
• Fecal microbiota transplantation to enhance cancer treatment outcomes across different cancer types: A systematic literature review.

  2025cites this paper
• Microbiome data integration via shared dictionary learning

  2025cites this paper
• Harnessing Next‐Generation 3D Cancer Models to Elucidate Tumor‐Microbiome Crosstalk

  2025cites this paper
• Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study

  2025cites this paper
• Facts & Hopes: towards the next quantum leap in melanoma.

  2025cites this paper
• Gastrointestinal adverse events associated with Lenvatinib versus Lenvatinib plus Pembrolizumab: A pharmacovigilance study in FDA adverse event reporting system

  2025cites this paper
• Expanding horizons of cancer immunotherapy: hopes and hurdles

  2025cites this paper
• Reply to Zhu.

  2025cites this paper
• The interplay between gut microbiota, antibiotics, and immune checkpoint inhibitors in patients with cancer: a narrative review with biological and clinical aspects.

  2025cites this paper
• Immune-related adverse events in patients with low baseline serum IL-6 treated with durvalumab plus tremelimumab for hepatocellular carcinoma: a case series

  2025cites this paper
• Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial

  2025cites this paper
• Baseline gut microbiome and metabolites are correlated with changes in alcohol consumption in participants in a randomized Zonisamide clinical trial

  2025cites this paper
• Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies

  2025influential citation
• Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs).

  2025cites this paper
• Prediction, prevention, and precision treatment of immune checkpoint inhibitor neurological toxicity using autoantibodies, cytokines, and microbiota

  2025cites this paper
• Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation

  2025cites this paper
• Unraveling the potential of bioengineered microbiome-based strategies to enhance cancer immunotherapy.

  2025cites this paper
• The association between metformin use, immune mediated colitis and overall survival in patients treated with checkpoint inhibitor.

  2025cites this paper
• Optimizing Cancer Treatment Through Gut Microbiome Modulation

  2025cites this paper
• Gut and Intratumoral microbiota: Key to lung Cancer development and immunotherapy.

  2025cites this paper
• The Current and Future of Biomarkers of Immune Related Adverse Events.

  2025cites this paper
• Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy

  2025cites this paper
• Microbial biomarker development for detection and prognosis of early-stage non-small cell lung cancer

  2025cites this paper
• Single-cell transcriptomic analysis reveals gut microbiota-immunotherapy synergy through modulating tumor microenvironment

  2025cites this paper
• Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review

  2025cites this paper
• The Microbiome and Cancer: A Translational Science Review.

  2025cites this paper
• Intestinal and esophageal microbiota in esophageal cancer development and treatment

  2025cites this paper
• Exploring the etiology of colitis: insights from gut microbiota research

  2025cites this paper
• Beyond the tumor: the gut microbiome as a key player in immunotherapy efficacy and resistance

  2025cites this paper
• Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma

  2025cites this paper
• Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence

  2025cites this paper
• Worse Survival and Gastrointestinal Toxicity Outcomes Among Patients Receiving Proton Pump Inhibitors During Checkpoint Inhibitor Therapy.

  2025cites this paper
• Microbiota interaction with Tregs: a target for colitis

  2025cites this paper
• Characteristics of the gut microbiota in patients with advanced non-small cell lung cancer who responded to immune checkpoint inhibitors

  2025cites this paper
• Role of Human Microbiome in Development and Management of Head and Neck Squamous Cell Carcinoma

  2025cites this paper
• Association of gut microbiota and immune gene expression with response to targeted therapy in BRAF mutated melanoma

  2025cites this paper
• Vitamin D, Gut Microbiota, and Cancer Immunotherapy—A Potentially Effective Crosstalk

  2025cites this paper
• Management of gastrointestinal adverse effects in immune-based combination therapy for advanced renal carcinoma: when the oncologist meets the gastroenterologist

  2025cites this paper
• Clinical perspective and treatment of immune-related colitis after cancer immunotherapy.

  2025cites this paper
• Impact of antibiotic therapy in patients with cholangiocarcinoma treated with chemoimmunotherapy.

  2025cites this paper
• Gut microbiota in melanoma: Effects and pathogeneses.

  2025cites this paper